Literature DB >> 16042723

Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score.

Christopher L Coogan1, Kalyan C Latchamsetty, Jason Greenfield, John M Corman, Barlow Lynch, Christopher R Porter.   

Abstract

OBJECTIVE: To evaluate taking more biopsy cores for predicting the radical prostatectomy (RP) Gleason score compared with the biopsy Gleason score, as although random sextant biopsies are the standard for a tissue diagnosis of prostate cancer, and taking more biopsies increases the detection rate, it is uncertain whether taking more cores improves the prediction of the RP Gleason score. PATIENTS AND METHODS: We analysed retrospectively 404 patients from three centres (Seattle 162, Washington 107 and Chicago 135) who had RP for prostate cancer. Six, eight or 10 biopsies were taken based on the physician's preference and the patient's characteristics.
RESULTS: Before RP, 158 (39%) patients had six, 65 (16%) had eight and 181 (45%) had 10 biopsy cores taken. The accuracy of the Gleason sum of the three groups was 65/158 (41%), 26/65 (40%) and 104/181 (57.5%), respectively (P < 0.004, 10-core vs six-core). However, when comparing the Gleason score separately (i.e. 4 + 3 is not equal to 3 + 4), the accuracy of the three groups was 48/158 (30%), 20/65 (31%), and 95/181 (52.5%), respectively (P < 0.001, 10-core vs six core).
CONCLUSIONS: Taking more biopsy cores improves the accuracy of the biopsy Gleason score in predicting the final Gleason score at RP; the predictive accuracy of the final Gleason score may be increased from 41% to 58% by increasing the number of biopsies from six to 10.

Entities:  

Mesh:

Year:  2005        PMID: 16042723     DOI: 10.1111/j.1464-410X.2005.05624.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

Review 2.  MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results.

Authors:  Christiaan G Overduin; Jurgen J Fütterer; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

Review 3.  Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease.

Authors:  Leonard S Marks
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

4.  Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens.

Authors:  E David Crawford; Kyle O Rove; Al B Barqawi; Paul D Maroni; Priya N Werahera; Craig A Baer; Hari K Koul; Cory A Rove; M Scott Lucia; Francisco G La Rosa
Journal:  Prostate       Date:  2012-11-20       Impact factor: 4.104

5.  Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications.

Authors:  Stephen J Freedland; Christopher J Kane; Christopher L Amling; William J Aronson; Martha K Terris; Joseph C Presti
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

6.  Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer.

Authors:  Irwin H Lee; Rebecca Roberts; Rajal B Shah; Kirk J Wojno; John T Wei; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-29       Impact factor: 7.038

7.  Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?

Authors:  Byung-Soo Jin; Seok-Hyun Kang; Duk-Yoon Kim; Hoon-Gyu Oh; Chun-Il Kim; Gi-Hak Moon; Tae-Gyun Kwon; Jae-Shin Park
Journal:  Korean J Urol       Date:  2015-09-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.